Observational Evaluation of Atopic Dermatitis in Pediatric Patients

Description

Primary Objectives: * To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable. * To evaluate the time-course of AD and selected atopic comorbidities. Secondary Objectives: * To characterize disease burden and unmet need. * To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching). * To document the real-world effectiveness and safety of treatments.

Conditions

Dermatitis Atopic

Talk to us

Study Overview

On this page

Study Details

Study overview

Primary Objectives: * To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable. * To evaluate the time-course of AD and selected atopic comorbidities. Secondary Objectives: * To characterize disease burden and unmet need. * To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching). * To document the real-world effectiveness and safety of treatments.

Prospective, Observational, Longitudinal Study in Pediatric Patients With Moderate to Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Those Therapies Are Not Medically Advisable

Observational Evaluation of Atopic Dermatitis in Pediatric Patients

Condition
Dermatitis Atopic
Intervention / Treatment

-

Contacts and Locations

Birmingham

Allervie Clinical Research Site Number : 8400012, Birmingham, Alabama, United States, 35209

Birmingham

C Squared Research Center Site Number : 8400068, Birmingham, Alabama, United States, 35209

Birmingham

Cahaba Dermatology & Skin Health Center- Site Number : 8400046, Birmingham, Alabama, United States, 35244

Montgomery

C2 Research Center, LLC Site Number : 8400071, Montgomery, Alabama, United States, 36117

Phoenix

Phoenix Children's Hospital, Inc. Site Number : 8400015, Phoenix, Arizona, United States, 85016

Anaheim

Orange County Research Institute Site Number : 8400028, Anaheim, California, United States, 92801

Los Angeles

Axis Clinical Trials Site Number : 8400025, Los Angeles, California, United States, 90036

Madera

Madera Family Medical Group Site Number : 8400054, Madera, California, United States, 93637

Ventura

Carey Chronis, MD, FAAP Site Number : 8400033, Ventura, California, United States, 93003

Centennial

IMMUNOe International Research Centers - Centennial- Site Number : 8400026, Centennial, Colorado, United States, 80112

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with moderate to severe AD, according to the Investigator's assessment;
  • * Currently receiving systemic treatment (including phototherapy) for atopic dermatitis or currently on topical treatment, but otherwise candidates for systemic treatment.
  • * Concurrent participation in an interventional clinical trial which modifies patient care.

Ages Eligible for Study

0 Years to 11 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Sanofi,

Clinical Sciences & Operations, STUDY_DIRECTOR, Sanofi

Study Record Dates

2036-04-21